Related Experiment Video
Updated: May 25, 2026
12:57
Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
Published on: January 8, 2015
Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models
S Pablo Sardi1, Priyanka Singh, Seng H Cheng
1Genzyme, Sanofi Company, Framingham, Mass 01701, USA. pablo.sardi@genzyme.com
Neuro-Degenerative Diseases
|February 14, 2012
Summary
Mutations in the glucocerebrosidase gene (GBA1) increase risk for synucleinopathies like Parkinson's disease. Both gene function loss and gain contribute to alpha-synuclein issues, offering potential therapeutic targets.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Heterozygous glucocerebrosidase gene (GBA1) mutations are linked to synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB).
- Homozygous GBA1 mutations cause Gaucher disease (GD) due to reduced GBA1 lysosomal activity.
- The exact mechanisms connecting GBA1 mutations to PD and DLB pathogenesis remain incompletely understood.
Purpose of the Study:
- To summarize recent findings on the complex pathogenetic link between GBA1 mutations and synucleinopathies.
- To explore the roles of both gain and loss of function mechanisms in aberrant alpha-synuclein processing.
- To discuss potential therapeutic strategies and the reciprocal relationship between alpha-synuclein and GBA1 activity.
Main Methods:
- Review of recent scientific literature and findings.
- Analysis of mechanisms in neural cells involving mutant GBA1 expression and activity.
- Examination of insights from Gaucher disease animal models.
Main Results:
- Both gain and loss of function of mutant GBA1 promote aberrant alpha-synuclein processing in neural cells.
- Gaucher disease animal models show axonal pathology, neuroinflammation, and memory deficits.
- A potential reverse link exists where alpha-synuclein species may coregulate GBA1 activity.
Conclusions:
- Emerging evidence suggests GBA1 mutations contribute to synucleinopathies through complex mechanisms.
- Neural enzyme replacement therapy and pharmacological agents are potential treatments for GBA1-associated synucleinopathies.
- Understanding the GBA1-alpha-synuclein interplay may offer therapeutic targets for broader neurodegenerative diseases.
